Tilmicosin is a semisynthetic macrolide antibiotic that is slightly soluble in water.
| Mechanism of Action | Macrolide antibiotics inhibit bacterial growth by targeting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. Resistance to tilmicosin is commonly attributed to mutations in 50S rRNA preventing tilmicosin binding allowing the cell to synthesize proteins free of error. |
| Spectrum | Tilmicosin primarily targets gram negative bacteria especially those which cause bovine respiratory disease. |
| Impurity Profile | Individual Impurity: ≤3.0% Total Impurities: ≤10.0% Cis-isomer: 82.0-88.0% Trans-isomer: 12.0-18.0% |
| Microbiology Applications | Tilmicosin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against gram negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:
|
| Molecular Formula | C46H80N2O13 |
| References | Lovmar, Martin, and Tanel Tenson. "The Mechanism of Action of Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide Exit Path in the Ribosome."Journal of Molecular Microbiology 330.5 (2003): 1005-014. |
| MIC | Actinobacillus pleuropneumoniae| 2.4 - 38.8|| Clostridium difficile| 0.125 - >256|| Haemophilus parasuis| 4 - 310|| Mannheimia haemolytica| 2 - 32|| Micrococcus| 28|| Mycoplasma bovis| 0.06 - <128|| Mycoplasma hyopneumoniae| 0.2 - 46.1|| Mycoplasma hyorhinis| 0.35 - 46.1|| Mycoplasma hyosynoviae| 2 - ≤32|| Pasteurella haemolytica| 4|| Pasteurella multocida| 0.6 - 1240|| Rhodococcus equi| 0.4 - >64|| Staphylococcus aureus| ≤0.4|| Streptococcus suis| 78 - 620|| |
